Department of Internal Medicine, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Clin Microbiol Infect. 2014 Oct;20(10):O721-9. doi: 10.1111/1469-0691.12500. Epub 2014 Jan 22.
In patients with community-onset acute pyelonephritis (CO-APN), assessing the risk factors for poor clinical response after 72 h of antibiotic treatment (early clinical failure) is important. The objectives of this study were to define those risk factors, and to assess whether early clinical failure influences mortality and treatment outcomes. We prospectively collected the clinical and microbiological data of women with CO-APN in South Korea from March 2010 to February 2012. The numbers of cases in the early clinical success and early clinical failure groups were 840 (79.1%) and 222 (20.9%), respectively. Final clinical failure and mortality were higher in the early clinical failure group than in the early clinical success group (14.9% vs 2.3%, p <0.001; 6.8% vs 0.1%, p 0.001, respectively). In a multiple logistic regression model, the risk factors for early clinical failure among the total 1062 patients were diabetes mellitus (OR 1.5; 95% CI 1.1-2.1), chronic liver diseases (OR 3.3; 95% CI 1.6-6.7), malignancy (OR 2.2; 95% CI 1.1-4.4), Pitt score ≥2 (OR 2.5; 95% CI 1.6-3.8), presence of azotaemia (OR 1.8; 95% CI 1.2-2.7), white blood cell count ≥20 000/mm(3) (OR 2.5; 95% CI 1.6-4.0), serum C-reactive protein level ≥20 mg/dL (OR 1.7; 95% CI 1.2-2.4), and history of antibiotic usage within the previous year (OR 1.5; 95% CI 1.1-2.2). Analysing the subgroup of 743 patients with CO-APN due to Enterobacteriaceae, fluoroquinolone resistance of the uropathogen was another factor associated with early clinical failure (OR 1.7; 95% CI 1.1-2.5). Simple variables of underlying diseases, previous antibiotic usage and initial laboratory test outcomes can be used to decide on the direction of treatment in CO-APN.
在社区获得性急性肾盂肾炎(CO-APN)患者中,评估抗生素治疗 72 小时后临床反应不良(早期临床失败)的风险因素非常重要。本研究的目的是确定这些风险因素,并评估早期临床失败是否会影响死亡率和治疗结局。我们前瞻性地收集了 2010 年 3 月至 2012 年 2 月韩国 CO-APN 女性患者的临床和微生物学数据。早期临床成功组和早期临床失败组的病例数分别为 840 例(79.1%)和 222 例(20.9%)。早期临床失败组的最终临床失败和死亡率均高于早期临床成功组(14.9%比 2.3%,p<0.001;6.8%比 0.1%,p<0.001)。在多变量逻辑回归模型中,1062 例患者中早期临床失败的危险因素为糖尿病(OR 1.5;95%CI 1.1-2.1)、慢性肝病(OR 3.3;95%CI 1.6-6.7)、恶性肿瘤(OR 2.2;95%CI 1.1-4.4)、Pitt 评分≥2(OR 2.5;95%CI 1.6-3.8)、氮血症(OR 1.8;95%CI 1.2-2.7)、白细胞计数≥20000/mm3(OR 2.5;95%CI 1.6-4.0)、血清 C 反应蛋白水平≥20mg/dL(OR 1.7;95%CI 1.2-2.4)和前一年使用抗生素史(OR 1.5;95%CI 1.1-2.2)。在 743 例因肠杆菌科引起的 CO-APN 患者的亚组分析中,尿病原体对氟喹诺酮的耐药性也是与早期临床失败相关的另一个因素(OR 1.7;95%CI 1.1-2.5)。潜在疾病、既往抗生素使用和初始实验室检测结果等简单变量可用于决定 CO-APN 的治疗方向。